PDCD1 and skin squamous cell carcinoma: Cemiplimab (trade name Libtayo) is an anti-PD-1 antibody with high affinity and is the first immune checkpoint therapeutic drug designed for the specific treatment of metastatic cutaneous squamous cell carcinoma (CSCC) [341].